In addition, AML cells bearing the NUP98::NSD1 fusion show significant sensitivity to inhibitors targeting the Polycomb Repressive complex 2 (PRC2), particularly EZH (Enhancer of Zeste Homolog) 2/1 enzymatic inhibitors, such as UNC1999. Here, NSD1 is linked to acute myeloid leukemia.